Search company, investor...
Altor BioScience company logo

Altor BioScience

altorbioscience.com

Founded Year

2002

Stage

Acquired | Acquired

Total Raised

$105.04M

Valuation

$0000 

About Altor BioScience

Altor BioScience is a biopharmaceutical company engaged in the discovery, development and commercialization of high-value, targeted immunotherapeutic agents for the treatment of cancer, viral infections, inflammatory and autoimmune diseases.

Headquarters Location

2810 North Commerce Parkway

Miramar, Florida, 33025,

United States

954-443-8600

Missing: Altor BioScience's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Altor BioScience's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Altor BioScience

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Altor BioScience is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

838 items

Altor BioScience Patents

Altor BioScience has filed 58 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immunology
  • Monoclonal antibodies
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/21/2019

11/15/2022

Clusters of differentiation, Immunology, Immune system, Monoclonal antibodies, Transcription factors

Grant

Application Date

10/21/2019

Grant Date

11/15/2022

Title

Related Topics

Clusters of differentiation, Immunology, Immune system, Monoclonal antibodies, Transcription factors

Status

Grant

Latest Altor BioScience News

K Cells to register a healthy CAGR for the forecast period, 2022-2030|Chipscreen Biosciences, Affimed NV, Altor BioScience

Oct 19, 2022

|Chipscreen Biosciences, Affimed NV, Altor BioScience Pune, Maharashtra, October 19 2022 (Wiredrelease) Market.Biz –:What Is The Current Situation Of K Cells Global Market After Covid 19, The Russia-Ukraine War, and The Sri Lankan Economy Crisis The  K Cells Market  research report is a professional analysis that includes industry, type, application, region, country, etc. Additionally, the report provides market analysis, revenue, trade, competition, investment, and forecasts. K Cells market research covers the impact of COVID-19 on upstream, midstream, and downstream industries. In addition, this study provides a comprehensive market overview with emphasis on various statistics covering market conditions such as drivers, restraints, opportunities, threats, and industry reports and trends. What are the K Cells Market’s current condition and demand before and after a conflict between Ukraine and Russia and having a negative or positive impact on business in the top regions? Companies struggle and grow to operate due to a lack of stability and the current situation of Market trade and investment in the global market Click Here To Get a Sample Or PDF Copy Including The Analysis of COVID-19 Impact: https://market.biz/report/global-k-cells-market-qy/389580/#requestforsample Report Metrics: -Base Year Considered – 2021 Market Top Region/Country including: – •Europe (Germany, UK, France, Italy, Russia and Spain etc.) •Asia-Pacific (China, Japan, Korea, India, Australia, Southeast Asia, etc.) •South America (Brazil, Argentina and Colombia etc.) •Middle East & Africa (South Africa, UAE and Saudi Arabia etc.) Marketing Development Key K Cells:-  • To explain K Cells Introduction, Product Types, and Applications, Market Analysis, Country Market Analysis, Market Opportunities, Market Risk, Market Driving Force. • To analyze the K Cells manufacturers, with profiles, key business, news, sales, price, revenue, and market share. • To show the competitive situation among the top manufacturers in the world, with sales, revenue, and market share K Cells  • To show the market by type and application, with sales, price, revenue, market share, and growth rate by type and application  • Analysis of key countries by manufacturers, types, and applications, covering North America, Europe, Asia-Pacific, Middle East & South America, with sales, revenue, and market share by manufacturers, types, and applications. • To analyze the cost of production, raw material and production process, etc. • To describe K Cells sales channels, distributors, customers, resellers, etc. Each segment of the global K Cells market is detailed so that industry participants and interested parties can understand the regional growth prospects and their valuable contribution to the overall K Cells market. the world together. Our market analysts have used primary and secondary trading methods to gather insightful information on various industry stories. They also provided a brief business position on these measures. Key Objectives Of The K Cells Global Market:  • To analyze the global K Cells market consumption, industry size estimation, and forecast till 2030. • To understand the general trends of the global K Cells market by understanding its segments and sub-segments. • Focuses on the leading manufacturers of the Global K Cells market to analyze, describe and develop the company’s share, revenue, market value, and competitive landscape over the years. • To analyze the K Cells market regarding upcoming prospects, various growth trends, and their contribution to the international market. • To analyze the production/consumption analysis of the global K Cells market with respect to key regions. • To get detailed statistics about the key factors governing the growth potential of the global K Cells market. If You Have Any Questions About This Report, Please Reach Out to Us @  https://market.biz/report/global-k-cells-market-qy/389580/#inquiry Contact Us: New York City, NY 10170, United States USA/Canada Tel No:+1(857)4450045, +91 9130855334

Altor BioScience Frequently Asked Questions (FAQ)

  • When was Altor BioScience founded?

    Altor BioScience was founded in 2002.

  • Where is Altor BioScience's headquarters?

    Altor BioScience's headquarters is located at 2810 North Commerce Parkway, Miramar.

  • What is Altor BioScience's latest funding round?

    Altor BioScience's latest funding round is Acquired.

  • How much did Altor BioScience raise?

    Altor BioScience raised a total of $105.04M.

  • Who are the investors of Altor BioScience?

    Investors of Altor BioScience include NantWorks, Sanderling Ventures, National Cancer Institute, TVM Capital, Radius Ventures and 7 more.

  • Who are Altor BioScience's competitors?

    Competitors of Altor BioScience include Inhibikase Therapeutics, Symphogen, Actinobac Biomed, Acetylon Pharmaceuticals, Anacor Pharmaceuticals, Alligator Bioscience, Pulmatrix, Affimed Therapeutics, Xencor, Affinium Pharmaceuticals and 14 more.

Compare Altor BioScience to Competitors

A
Actinobac Biomed

Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Its drug candidates are based upon Leukothera (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

Y
Y's Therapeutics

Y's Therapeutics focuses on developing monoclonal antibody therapies and other molecular-targeted biological drugs for the treatment of inflammation-mediated diseases, cancer, and other unmet medical needs. The company also have small molecule compounds in the company's R&D pipeline to diversify the company's portfolio.

P
Proteologics

PROTEOLOGICS develops a class of drugs for viral and other ubiquitin-mediated diseases utilizing technology and knowledge of the ubiquitin system.

N
Novation Pharmaceuticals

Novation is focusing on the development of small molecular weight drugs that affect the stability of messenger RNA. Initial development efforts are on the treatment and prevention of cancer and chronic inflammatory diseases.

I
Institute for OneWorld Health

A No-profit/no-loss Pharmaceutical Company Targeting Five Diseases In Need Of Drug Development. The company's First Drug, Paromomycin, Is A Treatment For Visceral Leishmaniasis Which Is An Illness Impacting The World's Poorest And Spread By Sand Flies. nnIt's Next Focus Is Malaria Where It Aims To Create And Market Semisynthetic Artemisinin. This Is A Key Malaria Battling Ingredient Which Is In Short Supply.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.